UAUğur Avcıbaşı

Uğur Avcıbaşı

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Uğur Avcıbaşı has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Synthesis and biodistribution of novel magnetic-poly(HEMA–APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy

    by Uğur Avcıbaşı, Nesibe Avcıbaşı, Hilmi Arkut Akalın, Melis Ediz, Hasan Demiroğlu, Fikriye Gül Gümüşer, Emir Özçalışkan, Ceren Türkcan, Deniz Aktaş Uygun, Sinan Akgöl


  • Radiolabeling of new generation magnetic poly(HEMA–MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats

    by Uğur Avc, Hasan Demiroğlu, Melis Ediz, Hilmi Arkut Akal, Emir Özçal, Hilal Şenay, Ceren Türkcan, Yeşim Özcan, Sinan Akgöl, Nesibe Avcıbaşı

    In this study, N‐methacryloyl‐l‐phenylalanine (MAPA) containing poly(2‐hydroxyethylmethacrylate) (HEMA)‐based magnetic poly(HEMA–MAPA) nanobeads [mag‐poly(HEMA–MAPA)] were radiolabeled with 131I [131I‐mag‐poly(HEMA–MAPA)], and the radiopharmaceutical potential of 131I‐mag‐poly(HEMA–MAPA) was investigated. Quality control studies were carried out by radiochromatographic method to be sure that 131I binded to mag‐poly(HEMA–MAPA) efficiently. In this sense, binding yield of 131I‐mag‐poly(HEMA–MAPA) was found to be about 95–100%. In addition to this, optimum radiodination conditions for 131I‐mag‐poly(HEMA–MAPA) were determined by thin‐layer radiochromatography studies. In addition to thin‐layer radiochromatography studies, lipophilicity (partition coefficient) and stability studies for 131I‐mag‐poly(HEMA–MAPA) were realized. It was determined that lipophilicities of mag‐poly(HEMA–MAPA) and 131I‐mag‐poly(HEMA–MAPA) were 0.12 ± 0.01 and 1.79 ± 0.76 according to ACD/logP algorithm program, respectively. Stability of the radiolabeled compound was investigated in time intervals given as 0, 30, 60, 180, and 1440 min. It was found that 131I‐mag‐poly(HEMA–MAPA) existed as a stable complex in rat serum within 60 min. After that, biodistribution and scintigraphy studies were carried out by using albino Wistar rats. It was determined that the most important 131I activity uptake was observed in the breast, the ovary, and the pancreas. Scintigraphy studies well supported biodistribution results. Copyright © 2013 John Wiley & Sons, Ltd.


  • Investigation of Therapeutic Efficiency of Bleomycin and Bleomycin-Glucuronide Labeled with 131 I on the Cancer Cell Lines

    by Melis Ediz, Uğur Avcıbaşı, Perihan Ünak, Fazilet Zümrüt Biber Müftüler, Emin İlKer Medine, Ayfer Yurt Kılçar, Hasan Demiroğlu, Fikriye Gül Gümüşer, Serhan Sakarya

    The aim of this study is to determine the incorporations of radiolabeled bleomycin (131I-BLM) and bleomycin-glucuronide (131I-BLMGLU) on PC-3 (human prostate carcinoma cell line), Caco-2 (human colon adenocarcinoma cell line), Hutu-80 (Human Duodenum adenocarcinoma cell line), and A549 (Human lung adenocarcinoma epithelial cell line) cancerous cell lines. For this purpose, BLM and BLMGLU enyzmatically synthesized were labeled with 131I, quality control studies were done and the incorporation yields of 131I-BLM and 131I-BLMGLU on these cell lines were measured. Quality-control studies showed that the radiolabeling yields were obtained as 95% and 90% for 131I-BLM and 131I-BLMGLU, respectively. Also, as a result of the cell culture studies, it was found that 131I-BLM and 131I-BLMGLU had higher incorporation on PC-3 cells than that of other cell lines. In addition to this, it was reported that the incorporation yield of 131I-BLMGLU was higher than that 131I-BLM. At the end of the study, cytotoxicities of BLM and BLMGLU on PC-3 cancerous cell line were inspected and fluorescent images of BLM and BLMGLU were taken on PC-3 cells by using fluorescein isothiocyanate. In conclusion, cell culture studies demonstrated that the incorporation values of 131I-BLMGLU on the four cell lines were about five to six times higher than 131I-BLM. Radiolabeled glucuronide derivatives can be used in cancer therapy and tumor imaging, depending on the properties of radioiodine for the β-glucuronidase-rich tissues because glucuronidation leads to rapid and higher incorporation on adenocarcinoma cells.


  • Metabolic Comparison of Radiolabeled Bleomycin and Bleomycin-Glucuronide Labeled with 99m Tc

    by Feray Koçan, Ugur Avcıbaşı, Perihan Ünak, Fazilet Zümrüt Biber Müftüler, Çigdem A. İçHedef, Hasan Demiroğlu, Fikriye G. Gümüşer

    The metabolic comparison of bleomycin (BLM) and bleomycin-glucuronide (BLMG) radiolabeled with 99mTc (99mTc-BLM and 99mTc-BLMG, respectively) has been investigated in this study. Quality control procedures were carried out using thin-layer radiochromatography and high-performance liquid chromatography. To compare the metabolic behavior of BLM and its glucuronide conjugate radiolabeled with 99mTc, scintigraphic, and biodistributional techniques were applied using male New Zealand rabbits and Albino Wistar rats. The results obtained have shown that these compounds were successfully radiolabeled with a labeling yield of about 100%. Maximum uptakes of 99mTc-BLM and 99mTc-BLMG metabolized as N-glucuronide were observed within 2 hours in the liver, the bladder, and the spinal cord for 99mTc-BLM and the lung, the liver, the kidney, the large intestine, and the spinal cord for 99mTc-BLMG, respectively. Scintigraphy and biodistributional studies performed on the experimental animals have shown that radiopharmaceutical potentials of these compounds are completely different. At the same time, uptake of the 99mTc-BLMG was found to be better than that of 99mTc-BLM.


  • In vivo biodistribution of 131I labeled bleomycin (BLM) and isomers (A2 and B2) on experimental animal models

    by U. Avcıbaşı, H. Demiroğlu, P. Ünak, F. Z. B. Müftüler, Ç. A. İçHedef, F. G. Gümüşer